Walther will provide a one-for-one match for donors who establish endowed children’s cancer research funds at Riley Children’s Foundation, a move that could result in at least $20 million for research of new treatments of children’s cancers.
Retired since 2015, Bob Kevoian made a rare appearance Wednesday on the syndicated “Bob & Tom” show to publicly reveal his diagnosis.
Mandy Pietrykowski succeeds Fred Duncan, who retired this week after leading the Indianapolis-based agency since 2009.
The Indianapolis-based radiopharmaceutical company said it plans to help open a facility in Belgium to make therapeutic agents for cancer patients.
Illuccix was first approved by the FDA in December 2021. The imaging agent is designed to target and “light up” cancerous cells, making it easier for oncologists to determine through a PET scan if the cells have spread to areas outside the prostate.
The Indianapolis-based pharmaceutical company is preparing for one of its most ambitious years in memory for 2023, with plans to advance five new drugs into late-stage clinical studies and move four into regulatory review.
A 10-year study by researchers from Poland, Norway and Sweden published in the New England Journal of Medicine questions the benefits of colonoscopy screening exams.
Point Biopharma is moving aggressively to get its lead drug, a radioactive isotope called lutetium 177, through late-stage trials for prostate cancer.
Three Indiana institutions are teaming up to try to develop a treatment for glioblastoma, a lethal cancer that begins with the brain or spinal cord, and is difficult to treat, often requiring a combination of surgery, chemotherapy and radiation.
The imaging agent is the six-year-old company’s first commercial launch, following millions of dollars’ worth of research and clinical tests. It was approved by the U.S. Food and Drug Administration in December.
The medical school said the commitment will help launch research efforts to develop better therapies for triple negative breast cancer, an aggressive form of breast cancer that is often not responsive to hormone therapies and is resistant to chemotherapy.
Brooke Beier, senior vice president of commercialization at the Purdue Research Foundation, said FDA approval of the therapy is one of the most meaningful approvals ever for a Purdue-related innovation.
It’s a big moment for On Target Laboratories, an 11-year-old biotech based in West Lafayette. The FDA approval marks the company’s first novel compound to get across the finish line. The drug is marketed under the brand name Cytalux.
Indianapolis’ newest publicly company, Point Biopharma Inc., is the latest player in a field expected to see explosive growth as doctors and researchers look for new ways to shrink tumors.
Few such drugs are approved now, but the approach is predicted to become a new way to treat patients with other hard-to-reach or inoperable cancers.
Dee Alderman’s doctors told her in November, as cases heated up, to stay home completely; her husband and son decontaminate every time they come in the house.
Merus N.V. specializes is so-called CD3 engaging T-cell therapies, a growing area of cancer research, based on immunotherapy, or using the immune system’s T cells to find and shrink tumors
Just 12 years after opening to great fanfare, the future of the $150 million center, a partnership between the Indiana University School of Medicine and Indiana University Health, is full of questions.
The grant will help fund an ongoing study to evaluate long-term health outcomes for cancer patients who receive life-saving chemotherapy treatments that often have difficult side effects.
Hardesty, 51, said operations at his culinary business, Studio C, will be scaled back while he undergoes treatment over the next several months.
